Permax Side Effects Lawsuits:
Linked to Heart Valve Damage
Permax (pergolide mesylate), is a popular drug developed by the
pharmaceutical company Eli Lilly to treat Parkinson's disease.
It comes in a tablet and usually is taken together with carbidopa
and levodopa. Generally it is taken at least once a day and may
be taken up to three times a day depending on how the patient
progresses. The drug has been linked to serious heart valve damage.
Medical studies indicate Permax may be
responsible for cardiac valvulopathy and
serious heart valve disease. Several
women being treated at the Mayo Clinic, all of whom were taking
Permax daily for between three to seven years, and none of whom
had prior history of heart disease, developed heart murmurs,
breathing difficulties and fluid retention in their legs. They
were diagnosed with serious heart valve disease and since the
diagnosis two of the three have required valve replacement surgery.
Doctors at the clinic felt the evidence
that linked Permax to heart valve disease was strong enough to
advise that patients with heart problems avoid Permax. The FDA
and Mayo Clinic have since ordered further investigation into
the side effects of this drug and in 2003, Eli Lilly & Co
(Permax's manufacturer) advised healthcare professionals of reports
of cardiac valvulopathy (heart valve disease) in patients receiving
Permax therapy. The FDA also recommended that Eli Lilly &
Co. revise the labeling of Permax to indicate the possible risk
of valvular heart disease.
Permax shares characteristics with the
weight loss drug Fen-phen as
well as a number of other drugs that have been associated with
valvular heart disease. These drugs are all associated with a
heightened stimulation of serotonin receptors which has been
linked to valve damage.
If you or a loved one
have experienced heart damage related to the use of Permax please
use our form for legal advice. You may contact our national network
of attorneys evaluating Permax claims at no obligation for a
free legal consultation.
an attorney client relationship. Read on >>